Reports Q2 revenue $157.4M, consensus $147.75M. “We are proud to report another strong quarter, marked by profitable year-over-year revenue growth of 38%. Our consistent performance across all areas of the business reflects the successful execution of our strategy, the differentiated value our OCS and NOP platforms, and our unique leadership position in the transplant market,” said Waleed Hassanein, MD, President and Chief Executive Officer. “Looking ahead, we are confident in our strategy and remain laser focused on achieving and surpassing the target of 10,000 US NOP transplants in 2028, while ramping up investments to drive the next several waves of growth aimed at delivering significant top-and bottom-line growth for our business.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- Buy Rating for TransMedics Group Amid Strong Q2 Prospects and Seasonal Challenges
- Cautious Optimism for TransMedics Group Amid Strong Growth Indicators
- TransMedics Group: Strong Market Position and Ethical Practices Justify Buy Rating Amid Controversies
- TransMedics price target raised to $142 from $129 at Canaccord
- Strong Financial Outlook: TransMedics Group’s Surpassing Sales and EPS Forecasts